Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.57 |
| ▸ | DHFR | P00374 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | CA1 | P00915 | 2/20 | 0.50 |
| ▸ | CA2 | P00918 | 2/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10285030 | 0.89 | ALDH1A1 (0.68) | L3MBTL1SMN1; SMN2DHFRTSHRTDP1 | |
| SCHEMBL13966984 | 0.85 | SMN1; SMN2 (0.59) | L3MBTL1SMN1; SMN2DHFRTSHRTDP1 | |
| SCHEMBL840440 | 0.84 | ALDH1A1 (0.59) | L3MBTL1ALDH1A1LMNANPSR1CA1 | |
| SCHEMBL28291995 | 0.83 | TSHR (0.67) | L3MBTL1SMN1; SMN2DHFRTSHRTDP1 | |
| SCHEMBL12700752 | 0.81 | SMN1; SMN2 (0.62) | L3MBTL1SMN1; SMN2DHFRTSHRTDP1 | |
| SCHEMBL2928482 | 0.79 | SMN1; SMN2 (0.66) | L3MBTL1SMN1; SMN2DHFRTSHRTDP1 | |
| SCHEMBL30849591 | 0.79 | ALDH1A1 (0.57) | SMN1; SMN2TSHRALDH1A1LMNANPSR1 | |
| SCHEMBL8072061 | 0.79 | ALDH1A1 (0.57) | SMN1; SMN2ALDH1A1LMNANPSR1CA1 | |
| SCHEMBL13648079 | 0.78 | SMN1; SMN2 (0.59) | L3MBTL1SMN1; SMN2DHFRTSHRTDP1 | |
| SCHEMBL10912165 | 0.78 | ALDH1A1 (0.77) | L3MBTL1SMN1; SMN2TDP1ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120070409-A1 | TETRACYCLIC FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR | JAPAN TOBACCO INC. (JP) | 2012-03-22 | — | — | US | disclosed |
| US-7977331-B1 | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2011-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120070409-A1 | TETRACYCLIC FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR | POLI, TERT, ZC3HAV1 | L3MBTL1 4435/4885SMN1; SMN2 4306/4885DHFR 171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.